PMC7591784_01
Patient's timeline. At the top, the main treatments that the patient has received, with a focus on the anti-graft-versus-host disease (GVHD) therapies. Then, the blue arrow represents the timeline. In the red rectangles, the main diagnosis that the patient has received and the biological characteristics [Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) and donor cell myelodysplastic syndrome (DC-MDS)]. In green, the persistence of the complete response (CR) over time, even after the DC-MDS onset (red star). K, karyotype; IP, immunophenotype.
fonc-10-564521-g001.jpg
PMC7591784_02_fonc-10-564521-g001.jpg
F1
Five years after allo-SCT (January 2018), the patient presented with anemia [hemoglobin (Hb) 12.2 g/dl], thrombocytopenia [platelet (PLT): 71 x 109/L], and hyperleukocytosis [white blood cell count (WBC): 20.45 x 109/L] (Figure 1). A gene panel deep sequencing has been performed at DC-MDS diagnosis to analyze some genes known to be related to myeloid malignancies (Supplementary Figure 1).
PMC7591784_02
Patient's timeline. At the top, the main treatments that the patient has received, with a focus on the anti-graft-versus-host disease (GVHD) therapies. Then, the blue arrow represents the timeline. In the red rectangles, the main diagnosis that the patient has received and the biological characteristics [Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) and donor cell myelodysplastic syndrome (DC-MDS)]. In green, the persistence of the complete response (CR) over time, even after the DC-MDS onset (red star). K, karyotype; IP, immunophenotype.
fonc-10-564521-g001.jpg
PMC7591784_02_fonc-10-564521-g001.jpg
F1
Five years after allo-SCT (January 2018), the patient presented with anemia [hemoglobin (Hb) 12.2 g/dl], thrombocytopenia [platelet (PLT): 71 x 109/L], and hyperleukocytosis [white blood cell count (WBC): 20.45 x 109/L] (Figure 1). A gene panel deep sequencing has been performed at DC-MDS diagnosis to analyze some genes known to be related to myeloid malignancies (Supplementary Figure 1).